Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Medilink Award win for Outstanding Achievement
Manchester, UK – 14 February 2020:Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won the Outstanding Achievement Award at the Medilink North of England Healthcare Business Awards 2020, held at the Lowry Hotel in Manchester, yesterday.
The Outstanding Achievement Award is presented to a Company for an achievement that has had a significant or vital impact on the business. Yourgene was awarded it for its acquisition of Elucigene Diagnostics, a Manchester-based molecular diagnostics manufacturer and developer, which it completed in April 2019. The complementary acquisition strengthened the Company’s position in the prenatal testing pathway and the teams have now fully integrated at its HQ situated at Citylabs 1.0.
The Medilink North of England Healthcare Business Award brings together leaders in the North of England to recognise companies and their teams for the achievements in the year and gain recognition deserved for improving patient care.
Lyn Rees, CEO of Yourgene, commented: “We are honoured to receive the Outstanding Achievement Award at the prestigious Medilink Healthcare Business Awards, recognising the significant step change for Yourgene that the Elucigene acquisition brings, and the strong platform we now have as an enlarged group to deliver future growth.”
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Tel: +44 (0)161 669 8122
Stifel Nicolaus Europe Limited (Sole Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
Tel: +44 (0)20 7710 7600
Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Lianne Cawthorne
Tel: +44 (0)20 7933 8780 or email@example.com
Mob: 07980 541 893 Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group’s products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.